Dia Marketing Of Pharmaceuticals 2012 Program Focuses On The Latest Dos And Don’ts Of Advertising And Marketing

Share Article

Three-day Program, Geared Towards the Needs of your Entire Promotional Team

News Image
Marketing Pharmaceuticals 2012 will provide insight into how to avoid the penalties for non-compliance.

DIA will convene regulatory, legal, and communications professionals to explore the latest “rules of the road” during Marketing of Pharmaceuticals 2012, February 15 – 17, 2012 in Washington, DC.

The three-day program, geared towards the needs of your entire promotional team, will provide you with:

  •     A better understanding of how the regulatory and legal environment has evolved and affects the marketing and promotion of pharmaceuticals, biologics, and medical devices
  •     Practical, day-to-day guidance based from the latest FDA enforcement actions, as well as federal and state civil and criminal actions and settlements
  •     Insight into FDA guidance documents and policies currently in development or being considered
  •     Latest enforcement activities by the centers within FDA that regulate medical marketing: drugs (CDER), biological products (CBER), and medical devices (CDRH)
  •     What’s new in Medical Policy Initiatives
  •     Information about Substantial Evidence and other Standards

As evidenced by the FDA’s recent Social Media Marketing Draft Guidance, the regulatory dos and don’ts of medical product marketing have been big question marks for companies. Hear what regulatory experts have to say about the implications of this draft guidance. Featured FDA speakers include:

  •     Jean-Ah Kang, PharmD, CDER
  •     Thomas W. Abrams, MBA, RPh, CDER
  •     Terri T. Garvin, CDRH
  •     Deborah Wolf, CDRH

“It’s not getting any easier to understand or be in compliance with all the various regulatory and legal requirements that apply to Rx and OTC drug and device promotional materials,” say Program Committee Member Wayne L. Pines, President, Regulatory Services and Healthcare, APCO Worldwide, Inc. “Marketing Pharmaceuticals 2012 will provide insight into how to avoid the penalties for non-compliance.”

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China. http://www.diahome.org

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Deborah Auerbach-Deutsch
Visit website